June 5, 2017

CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy  ̶  chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. 

June 5, 2017

ALEXANDRIA Va. -- The American Society of Clinical Oncology, Inc. (ASCO®) and Illumina, Inc. today announced a joint contribution of variant interpretations of 6,000 associations of somatic genetic alterations—variants linked to tumors—to the CIViC (Clinical Interpretation of Variants in Cancer) resource, an openly accessible database hosted by Washington University in St. Louis.

 

June 3, 2017

CHICAGO – Findings from a retrospective study of 1,200 women provide reassurance to breast cancer survivors who are contemplating pregnancy. In the study, women who became pregnant after an early breast cancer diagnosis, including those with estrogen receptor (ER)-positive tumors, did not have a higher chance of cancer recurrence and death than those who did not become pregnant.

June 3, 2017

CHICAGO  – The American Society of Clinical Oncology’s (ASCO®) Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility.

May 25, 2017

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) today announced the launch of its Center for Research & Analytics (CENTRA), which aims to make an array of cancer data available to the oncology community and provide consultation and support for research and analysis. To help guide the program, ASCO has appointed Elizabeth Garrett-Mayer, PhD, to serve as ASCO’s Director of Biostatistics and Data Management division. 

May 24, 2017

ASCO strongly opposes the Administration’s proposed cuts to federal agencies that support biomedical research and Medicaid for Fiscal Year 2018, including a 21 percent proposed funding cut for the National Institutes of Health (NIH), a 20 percent proposed funding cut for the National Cancer Institute (NCI), and reducing Medicaid funding by more than $600 billion.  Such extreme reductions to programs that are critical to research will fundamentally damage our nation’s progress in treating patients and will irreversibly harm our nation’s already fragile biomedical research infrastructure.

May 22, 2017

NORTHFIELD, Ill. and ALEXANDRIA, Va. Draft recommendations as part of a focused update to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017.

May 15, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Rubinstein will oversee the team working to securely process and analyze the CancerLinQ® platform's patient data from millions of electronic health records to give personalized insights than can improve the quality of care for patients with cancer.

May 9, 2017

The American Society of Clinical Oncology (ASCO) congratulates Scott Gottlieb, MD, on his confirmation as Commissioner of the Food and Drug Administration (FDA). With more than 1.7 million new cancer diagnoses made in the United States every year, millions of individuals with cancer and their families rely on the FDA to provide critical oversight and evaluation of the safety and efficacy of new medical products as well as those in routine clinical use.

May 9, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), and the College of American Pathologists (CAP) announced today that they will be partnering to bolster the expertise being provided to the CancerLinQ® platform, a real-world, big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes.

May 8, 2017

Alexandria, VA – The American Society of Clinical Oncology (ASCO) has released findings from an ASCO-National Cancer Institute (NCI) collaboration that explored centralizing the development of coverage analyses for multi-site cancer clinical trials. In an ASCO special article published today in the Journal of Oncology Practice“Feasibility of a Centralized Clinical Trials Coverage Analysis: A Joint Initiative of the American Society of Clinical Oncology and the National Cancer Institute,” the authors assert that developing a centralized system for coverage analysis is a feasible way to address key issues and reduce administrative burdens for cancer research sites managing billing compliance, with potential for widespread benefits across the cancer research field.

May 4, 2017

ASCO applauds members of the House and Senate for their vote this week to provide a $2 billion increase in funding to the National Institutes of Health (NIH). This marks the first time in more than a dozen years that Congress has provided the NIH with a back-to-back funding increase.

May 2, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Santa Clara Valley Medical Center (SCVMC) in San Jose, Calif. has signed an agreement to participate in the CancerLinQ® platform. 

May 1, 2017

ASCO applauds Congress for its leadership in providing an additional $2 billion in funding for the National Institutes of Health (NIH). This increase reaffirms the United States' longstanding, bipartisan commitment to scientific research, and will reinvigorate the scientific community as it continues to rebuild after a decade of flat funding. It also offers hope to millions of Americans and their families who face a cancer diagnosis every year. 

April 28, 2017

ASCO strongly opposes the American Health Care Act (AHCA) as currently proposed, and urges a “No” vote on the bill in the House of Representatives because it does not meet our previously announced principles. We believe health care reform must ensure meaningful access to high-quality care for any American with cancer. 

Pages